类风湿关节炎疾病控制后逐步减停TNF抑制剂与csDMARDs的随机对照TARA研究首年结果
TARA研究为多中心单盲随机对照试验,纳入189例已达疾病控制(DAS≤2.4且SJC≤1)且同时使用csDMARD与TNF抑制剂的RA患者,随机分为逐步减停csDMARD组(n=94)或减停TNF抑制剂组(n=95)。1年随访时两组累积复发率分别为33%(95%CI 24%–43%)与43%(95%CI 33%–53%)(p=0.17),DAS、HAQ-DI、EQ-5D无差异;减停TNF抑制剂并不优于减停csDMARDs。
要点
- RA疾病控制后逐步减停csDMARDs或TNF抑制剂,9个月内复发率相似。
- 1年时减停csDMARDs组复发率较低但差异无统计学意义(p=0.17)。
- 从社会视角可优先减停TNF抑制剂以降低成本并减少长期副作用。
核心结论
- 在RA疾病控制后,逐步减停TNF抑制剂并不优于逐步减停csDMARDs。
- 1年时减停csDMARDs组复发率较减停TNF抑制剂组低10%,但差异无统计学意义。
研究设计与样本
- 多中心单盲(研究护士盲)随机对照试验,纳入同时使用csDMARD和TNF抑制剂且疾病控制(DAS≤2.4且SJC≤1)的RA患者。
- 189例患者随机分为逐步减停csDMARDs组(n=94)或减停TNF抑制剂组(n=95)。
- 减停方式为在疾病仍控制时依次将剂量减半、减至四分之一、之后停药。
主要发现
- csDMARD减停组与抗TNF减停组的累积复发率分别为33%(95%CI 24%–43%)和43%(95%CI 33%–53%)(p=0.17)。
- 1年时及随时间推移,两组平均DAS、HAQ-DI和EQ-5D无差异。
关键数值与推荐
- 疾病控制定义为DAS≤2.4且肿胀关节计数(SJC)≤1。
- 复发定义为DAS>2.4和/或SJC>1。
临床怎么用
- 对于同时使用csDMARD和TNF抑制剂且已达疾病控制的RA患者,可考虑逐步减停TNF抑制剂。
- 从社会视角,优先减停TNF抑制剂可能降低成本并减少长期副作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim of this study is to evaluate the effectiveness of two tapering strategies after achieving controlled disease in patients with rheumatoid arthritis (RA), during 1 year of follow-up. METHODS: In this multicentre single-blinded (research nurses) randomised controlled trial, patients with RA were included who achieved controlled disease, defined as a Disease Activity Score (DAS) ≤ 2.4 and a Swollen Joint Count (SJC) ≤ 1, treated with both a conventional synthetic disease-modifying antirheumatic drugs (csDMARD) and a TNF inhibitor. Eligible patients were randomised into gradual tapering csDMARDs or TNF inhibitors. Medication was tapered if the RA was still under control, by cutting the dosage into half, a quarter and thereafter it was stopped. Primary outcome was proportion of patients with a disease flare, defined as DAS > 2.4 and/or SJC > 1. Secondary outcomes were DAS, European Quality of Life-5 Dimensions (EQ5D) and functional ability (Health Assessment Questionnaire Disability Index [HAQ-DI]) after 1 year and over time. RESULTS: A total of 189 patients were randomly assigned to tapering csDMARDs (n = 94) or tapering anti-TNF (n = 95). The cumulative flare rates in the csDMARD and anti-TNF tapering group were, respectively, 33 % (95% CI,24% to 43 %) and 43 % (95% CI, 33% to 53 % (p = 0.17). Mean DAS, HAQ-DI and EQ-5D did not differ between tapering groups after 1 year and over time. CONCLUSION: Up to 9 months, flare rates of tapering csDMARDs or TNF inhibitors were similar. After 1 year, a non-significant difference was found of 10 % favouring csDMARD tapering. Tapering TNF inhibitors was, therefore, not superior to tapering csDMARDs. From a societal perspective, it would be sensible to taper the TNF inhibitor first, because of possible cost reductions and less long-term side effects. TRIAL REGISTRATION NUMBER: NTR2754.
引用
- van Mulligen E, de Jong PHP, Kuijper TM, et al. Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study. Ann Rheum Dis. 2019. PMID: 30954969. doi:10.1136/annrheumdis-2018-214970
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。